TechForce Robotics Enters Pharmaceutical Automation Market Through Initial Deployment at Oncotelic Therapeutics

Deployment of the Company's LIM-E autonomous laboratory support robot completes Phase 1 objectives under the joint development agreement and establishes a foundation for future pharmaceutical automation initiatives LOS ANGELES, June 01, 2026 (GLOBE NEWSWIRE) -- via IBN — TechForce Robotics, Inc. ("TechForce"), a subsidiary of Nightfood Holdings, Inc. (OTCQB: NGTF), today announced the successful completion of Phase 1 objectives under its joint development agreement with Oncotelic Therapeutics, Inc. (OTCQB: OTLC), marked by the initial deployment of LIM-E, the Company's autonomous laboratory support robot. The deployment represents TechForce's first operational expansion into pharmaceutical and laboratory automation, extending the Company's AI-enhanced robotics platform beyond hospitality and service-industry applications into a new high-value market vertical.